Recent Advances and Prognosis in Idiopathic Membranous Nephropathy

Advances in Chronic Kidney Disease

Volumn 19, Issue 2, 2012, Pages 114-119

  Segal, Paul E ^a   Choi, Michael J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Membranous nephropathy; Podocyte; Proteinuria; Subepithelial deposits

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; CORTICOTROPIN; CYCLOSPORIN; CYTOTOXIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HLA DQA1 ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHOLIPASE A2 RECEPTOR; PHOSPHOLIPASE A2 RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; RITUXIMAB; STEROID; TACROLIMUS; UNCLASSIFIED DRUG;

BLOOD PRESSURE REGULATION; CONSERVATIVE TREATMENT; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; IDIOPATHIC DISEASE; IDIOPATHIC MEMBRANOUS NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; MEMBRANOUS GLOMERULONEPHRITIS; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; REMISSION; REVIEW; SODIUM RESTRICTION;

AUTOANTIBODIES; BIOLOGICAL MARKERS; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; MALE; PROGNOSIS; PROTEINURIA; RECEPTORS, PHOSPHOLIPASE A2; REMISSION, SPONTANEOUS;

EID: 84858766888     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2012.01.007     Document Type: Review

References (45)

1. Heymann W., Hackel D.B., Harwood S., Wilson S.G., Hunter J.L. Production of nephrotic syndrome in rats by freund's adjuvants and rat kidney suspensions. Proc Soc Exp Biol Med 1959, 100:660-664.
2. Farquhar M.G., Saito A., Kerjaschki D., Orlando R.A. The heymann nephritis antigenic complex: megalin (gp330) and RAP. J Am Soc Nephrol 1995, 6:35.
3. Beck L.H., Bonegio R.G., Lambeau G., et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009, 361:11-21.
4. Shah P., Tramontano A., Makker S.P. Intramolecular epitope spreading in heymann nephritis. J Am Soc Nephrol 2007, 18:3060-3066.
5. Stanescu H.C., Arcos-Burgos M., Medlar A., et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 2011, 364:616-626.
6. Debiec H., Ronco P. PLA2R autoantibodies an PLA2R glomerular deposits in membranous nephropathy. N Engl J Med 2011, 364:689-690.
7. Beck L.H., Salant D.J. Membranous nephropathy: recent travels and new roads ahead. Kidney Int 2010, 77:765-770.
8. Stahl R., Hoxha E., Fechner K. PLA2R autoantibodies and recurrent membranous nephropathy after transplantation. N Engl J Med 2010, 363:496-498.
9. Qin W., Beck L.H., Zeng C., et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 2011, 22:1137-1143.
10. Knehtl M., Debiec H., Kamgang P., et al. A case of phospholipase A2 receptor-Positive membranous nephropathy preceding sarcoid-associated granulomatous tubulointerstitial nephritis. Am J Kidney Dis 2011, 57:140-143.
11. Prunotto M., Carnevali M.L., Candiano G., et al. Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol 2010, 21:507-519.
12. Bruschi M., Carnevali M.L., Murtas C., et al. Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: alfa-enolase and borderline antigens. J Proteomics 2011, 74:2008-2017.
13. Ronco P., Debiec H. Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy. J Am Soc Nephrol 2010, 21:564-569.
14. Debiec H., Lefeu F., Kemper M.J., et al. Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med 2011, 364:2101-2110.
15. Chen J.S., Chen A., Chang L.C., et al. Mouse model of membranous nephropathy induced by cationic bovine serum albumin: antigen dose-response relations and strain differences. Nephrol Dial Transplant 2004, 19:2721-2728.
16. Strobel S., Mowat A.M. Immune responses to dietary antigens: oral tolerance. Immunol Today 1998, 19:173-181.
17. Sjöwall C., Kastbom A., Almroth G., Wetterö J., Skogh T. Beware of antibodies to dietary proteins in " antigen-specific" immunoassays! false positive anticytokine antibody tests due to reactivity with bovine serum albumin in rheumatoid arthritis (the Swedish TIRA project). J Rheumatol 2011, 38:215-220.
18. Glassock R.J. Diagnosis and natural course of membranous nephropathy. Semin Nephrol 2003, 23:324-332.
19. Fervenza F.C., Sethi S., Specks U. Idiopathic membranous nephropathy: diagnosis and treatment. Clin J Am Soc Nephrol 2008, 3:905-919.
20. Cattran D.C. Outcomes research in glomerulonephritis. Semin Nephrol 2003, 23:340-354.
21. Noel L.H., Zanetti M., Droz D., Barbanel C. Long-term prognosis of idiopathic membranous glomerulonephritis study of 116 untreated patients. Am J Med 1979, 66:82-90.
22. Cattran D. Management of membranous nephropathy: when and what for treatment. J Am Soc Nephrol 2005, 16:1188-1194.
23. Donadio J.V., Torres V.E., Velosa J.A., et al. Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int 1988, 33:708-715.
24. Schieppati A., Mosconi L., Perna A., et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 1993, 329:85-89.
25. Wakai S., Magil A.B. Focal glomerulosclerosis in idiopathic membranous glomerulonephritis. Kidney Int 1992, 41:428-434.
26. Lee H.S., Koh H.I. Nature of progressive glomerulosclerosis in human membranous nephropathy. Clin Nephrol 1993, 39:7-16.
27. Dumoulin A., Hill G.S., Montseny J.J., Meyrier A. Clinical and morphological prognostic factors in membranous nephropathy: significance of focal segmental glomerulosclerosis. Am J Kidney Dis 2003, 41:38-48.
28. Heeringa S.F., Branten A.J., Deegens J.K., Steenbergen E., Wetzels J.F. Focal segmental glomerulosclerosis is not a sufficient predictor of renal outcome in patients with membranous nephropathy. Nephrol Dial Transplant 2007, 22:2201-2207.
29. Troyanov S., Roasio L., Pandes M., Herzenberg A.M., Cattran D.C. Renal pathology in idiopathic membranous nephropathy: a new perspective. Kidney Int 2006, 69:1641-1648.
30. Pei Y., Cattran D., Greenwood C. Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int 1992, 42:960-966.
31. Cattran D.C. Management of membranous nephropathy: When and what for treatment. JASN 2005, 16:1188-1194.
32. Branten A.J., du Buf-Vereijken P.W., Klasen I.S., et al. Urinary excretion of beta2microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study. J Am Soc Nephrol 2005, 16:169-174.
33. Davison A.M., Cameron J.S., Kerr D.N., Ogg C.S., Wilkinson R.W. The natural history of renal function in untreated idiopathic membranous glomerulonephritis in adults. Clin Nephrol 1984, 22:61-67.
34. Honkanen E., Tornroth T., Gronhagen-Riska C., Sankila R. Long-term survival in idiopathic membranous glomerulonephritis: can the course be clinically predicted?. Clin Nephrol 1994, 41:127-134.
35. Reichert L.J., Koene R.A., Wetzels J.F. Prognostic factors in idiopathic membranous nephropathy. Am J Kidney Dis 1998, 31:1-11.
36. Branten A.J., Vervoort G., Wetzels J.F. Serum creatinine is a poor marker of GFR in nephrotic syndrome. Nephrol Dial Transplant 2005, 20:707-711.
37. Troyanov S., Wall C.A., Miller J.A., Scholey J.W., Cattran D.C. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int 2004, 66:1199-1205. Toronto Glomerulonephritis Registry Group.
38. Ponticelli C., Zucchelli P., Imbasciati E., et al. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 1984, 310:946-950.
39. Polanco N., Gutierrez E., Covarsi A., et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 2010, 21:697-704.
40. Blainey J.D., Brewer D.B., Hardwicke J., Soothill J.F. The nephrotic syndrome diagnosis by renal biopsy and biochemical and immunological analyses related to the response to steroid therapy. Q J Med 1960, 29:235-256.
41. Cameron J.S., Blandford G. The simple assessment of selectivity in heavy proteinuria. Lancet 1966, 2:242-247.
42. Bazzi C., Petrini C., Rizza V., Arrigo G., D'Amico G. A modern approach to selectivity of proteinuria and tubulointerstitial damage in nephrotic syndrome. Kidney Int 2000, 58:1732-1741.
43. Hoxha E., Harendza S., Zahner G., et al. An immunofluorescence test for phospholipase-A-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant 2011, 26:2526-2532.
44. Hofstra J.M., Beck L.H., Beck D.M., Wetzels J.F., Salant D.J. Anti-phospholipase A receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2011, 6:1286-1291.
45. Beck L.H., Fervenza F.C., Beck D.M., et al. Rituximab-induced depletion of antiPLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011, 22:1543-1550.